Between our access to additional capital under our committed equity financing facility with Aspire Capital Fund, LLC (“Aspire Capital”), the $10.0 million borrowed from the Lenders, the $10.9 million received from our February 2015 financing, and cash received from Vitaros® royalties and product sales, we believe we have sufficient cash reserves and access to cash to fund our base operations through the fourth quarter of 2016. This includes the completion of our fispemifene phase 2b clinical trial, support of

20

the commercialization of Vitaros®, and other general operating activities. As of September 30, 2015, net open purchase orders totaled approximately $8.3 million.